Efficacy and Safety of NTQ5082 in Complement Inhibitor‐Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria
American Journal of Hematology · 30.10.2026
DOI: 10.1002/ajh.70512 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 30.10.2026. Verfasst von Li Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianj…. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Nanjing Chia-Tai Tianqing Pharmaceutical Co. Ltd..
Abstract (Originalsprache)
Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematologic disorder characterized by complement‐mediated intravascular hemolysis, pancytopenia, and thrombosis. NTQ5082 is a novel oral selective complement factor B (CFB) inhibitor that suppresses alternative pathway activity, thereby inhibiting intravascular hemolysis in PNH. We conducted a randomized, open‐label Phase 2 study to investigate NTQ5082 monotherapy in adults with PNH who had not previously received complement inhibitors. Twenty‐five patients were assigned to receive oral NTQ5082 once daily (QD) at 100 mg (group A) or 200 mg (group B) for 12 weeks. In both groups, lactate dehydrogenase (LDH) levels rapidly decreased, and hemoglobin (Hb) levels increased within 1 week after treatment initiation, with no further transfusions needed. At week 12, the mean LDH concentration was 239.4 ± 63.5 U/L in group A and 245.8 ± 72.6 U/L in group B. The Hb concentration increased to ≥ 20 g/L from baseline in 100% of patients, while 50% and 61.5% of patients in groups A and B, respectively, achieved Hb concentrations ≥ 120 g/L. The most frequently reported treatment‐related adverse events (TRAEs) were headache (12%), upper respiratory tract infection (8%), and decreased neutrophil count (8%); no grade ≥ 3 adverse events (AEs) were reported. Oral NTQ5082 administered at 100 or 200 mg QD effectively controlled hemolysis, significantly increased Hb levels, and improved quality of life, with a satisfactory safety profile, suggesting that NTQ5082 may represent a promising therapeutic option for complement inhibitor‐naïve patients with PNH.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
- Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd., Nanjing, China.
ORCID-Profile: Gaixiang Xu, Linghui Xia, Rongfeng Zhou, Fengkui Zhang
Förderung
- Nanjing Chia-Tai Tianqing Pharmaceutical Co. Ltd.
Zitieren
APA
Zhang, L., Xu, G., Xia, L., Liu, L., Zhou, Y., Zhou, R., Chen, S., Zhang, F., & Tong, H. (2026). Efficacy and Safety of NTQ5082 in Complement Inhibitor‐Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria. American Journal of Hematology. https://doi.org/10.1002/ajh.70512
Vancouver
Zhang L, Xu G, Xia L, Liu L, Zhou Y, Zhou R, et al. Efficacy and Safety of NTQ5082 in Complement Inhibitor‐Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria. American Journal of Hematology. 2026. doi:10.1002/ajh.70512
BibTeX
@article{Zhang2026,
author = {Zhang, Li and Xu, Gaixiang and Xia, Linghui and Liu, Lin and Zhou, Yumeng and Zhou, Rongfeng and Chen, Shujun and Zhang, Fengkui and Tong, Hongyan},
title = {Efficacy and Safety of NTQ5082 in Complement Inhibitor‐Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70512}
}
EUVIMED